Biotechnology, gene editing, biopharma platforms, and clinical pipelines.
An article joins this feed when it matches these terms. Each one is also a search of its own.
COVINGTON, LA, UNITED STATES, October 8, 2026 /EINPresswire.com/ — Lanclos 1063, a Louisiana-based private investment house, announces an investment and partnership with AI:ON Innovations (aion.health... Lanclos 1063, LLC Announces Investment in Groundbreaking AI Medical Imaging COVINGTON, LA, UNITED STATES, October 8, 2026 /EINPresswire.com…
Aroa will use Mölnlycke’s US muscle to bulk up Endoform’s reach in post-acute care. Pic: Getty Images Special Report: Aroa Biosurgery is partnering with Swedish-headquartered Mölnlycke Healthcare US to co-promote its Endoform product in the US, expanding its reach in…
While Genetic Signatures and Microba cosy up for a merger, brooding BCAL looks to have other plans. Pic: Getty Images Genetic Signatures (ASX:GSS) has demanded that the third wheel in its proposed merger with Microba Life Sciences (ASX:MAP)…
Posted by Defense World Staff on Oct 19th, 2026 Check Out Our Latest Stock Report on PLUN Plutonian Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with one or more operating businesses…
Posted by Defense World Staff on Oct 19th, 2026 Get Our Latest Stock Report on Nurix Therapeutics Shares of Nurix Therapeutics stock opened at $24.42 on Monday. The firm has a fifty day moving average of $25.11 and a two-hundred day moving average of…
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ('ImmixBio”, 'Company”, 'we” or 'us” or 'IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a…
Posted by Defense World Staff on Oct 19th, 2026 Shares of IBRX opened at $9.18 on Monday. The firm has a market capitalization of $9.73 billion, a price-to-earnings ratio of -9.46 and a beta of 0.02. ImmunityBio has a 1-year low of $1.95 and a 1-year high…
Posted by Defense World Staff on Oct 19th, 2026 Grace Therapeutics, Inc. (NASDAQ: GRCE) filed a Form 4 showing Opaleye Management Inc. bought 71,065 shares from 10/14/2026 to 10/16/2026. The reported weighted average prices were $1.9349 on 10/14/2026, $1.9453 on 10/15/2026 and $1.8917 on 10/16/2026, for about $136,178. After the trades, Opaleye Management…
Posted by Defense World Staff on Oct 19th, 2026 Corcept Therapeutics Inc (NASDAQ: CORT) said director James N. Wilson sold 10,000 shares of common stock on 2026-10-15. The filing says the shares sold for $114.48 to $116.30 each, for a total value of about $1.15 million. It also…
Posted by Defense World Staff on Oct 19th, 2026 Beam Therapeutics Inc. (NASDAQ: BEAM) chief executive and director John M. Evans sold 50,000 shares from 2026-10-15 to 2026-10-16 at $23.57 to $23.98 each. The Form 4 says the shares were sold under a Rule 10b5-1 trading plan. It also says…